Vestal Point Capital, LP Reports New 6.3% Passive Stake in Nurix Therapeutics, Inc. (NRIX)

On May 15, 2026, Vestal Point Capital, LP, along with its Chief Investment Officer and Managing Partner, Ryan Wilder, filed a Schedule 13G with the SEC regarding their stake in Nurix Therapeutics, Inc. (NRIX). The filing reveals that as of March 31, 2026, the reporting persons beneficially own 6,500,000 shares of common stock, representing a 6.3% ownership interest in the company. This position marks a new significant holding for the investment manager, as the previous ownership was reported at 0%. The shares are held directly by a fund and a managed account advised by Vestal Point Capital, LP. The reporting persons have shared voting and dispositive power over the reported shares. The filing was made under Rule 13d-1(b), certifying that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The percentage calculation is based on approximately 103.4 million shares outstanding as of late March 2026.